Lower GI 2017

PEMBROLIZUMAB TRIAL SCHEMA

ANAL CANCER D1 MITOMYCIN 12MG/M2 + either 5FU 1G/M2 D2-5, D29-32 (incl) or CAPECITABIN E 825MG/M2 ON DAYS OF RT

ANAL CANCER D1 MITOMYCIN 12MG/M2 + either 5FU 1G/M2 D2-5, D29-32 (incl) or CAPECITABIN E 825MG/M2 ON DAYS OF RT

ANAL CANCER D1 MITOMYCIN 12MG/M2 + either 5FU 1G/M2 D2-5, D29-32 (incl) or CAPECITABIN E 825MG/M2 ON DAYS OF RT

Day 1 CRT Day 8 CRT

Day 1 CRT Day 8 CRT

Day 1 CRT Day 8 CRT

Day 15 CRT Day 22 CRT

Day 15 CRT Day 22 CRT

Day 15 CRT Day 22 CRT

Day 29 CRT

Day 29 CRT

Day 29 CRT

COHORT 1

COHORT 2

COHORT 3

Day 36 CRT Day 43 CRT

Day 36 CRT Day 43CRT

Day 36 CRT Day 43 CRT

Day 50 CRT Day 57 CRT

Day 50 CRT Day 57 CRT

Day 50 CRT Day 57 CRT

Pembrolizumab 200mg q21d Key

Day 64 CRT

Day 64 CRT

Day 64 CRT

Follow up – 3 months toxicity check + MRI at 6 and 12 months